IVA Stock Overview

A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. More details

IVA fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	3/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Revenue is forecast to grow 49.57% per year

Risk Analysis

Negative shareholders equity

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

My Notes

Capture your thoughts, links and company narrative

Inventiva S.A. Competitors

Verastem

NasdaqCM:VSTM

US$274.2m

TriSalus Life Sciences

NasdaqGM:TLSI

US$172.3m

AVITA Medical

NasdaqCM:RCEL

US$278.6m

Voyager Therapeutics

NasdaqGS:VYGR

US$231.1m

Price History & Performance

Summary of share price highs, lows and changes for Inventiva
Historical stock prices
Current Share Price	€2.51
52 Week High	€4.50
52 Week Low	€1.53
Beta	0.79
1 Month Change	16.20%
3 Month Change	-8.39%
1 Year Change	-24.17%
3 Year Change	-79.77%
5 Year Change	n/a
Change since IPO	-81.30%

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Jul 08

Recent updates

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Jul 08

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Feb 22

Inventiva, Sino Biopharm sign licensing pact to develop, commercialize NASH treatment

Sep 21

Inventiva lays out trial design for late-stage lanifibranor study in NASH

Jan 05

Shareholder Returns

	IVA	US Biotechs	US Market
7D	2.4%	0.4%	1.5%
1Y	-24.2%	-2.7%	22.4%

Return vs Industry: IVA underperformed the US Biotechs industry which returned -2.7% over the past year.

Return vs Market: IVA underperformed the US Market which returned 22.4% over the past year.

Price Volatility

Is IVA's price volatile compared to industry and market?
IVA volatility
IVA Average Weekly Movement	7.6%
Biotechs Industry Average Movement	11.1%
Market Average Movement	5.9%
10% most volatile stocks in US Market	18.1%
10% least volatile stocks in US Market	3.0%

Stable Share Price: IVA has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: IVA's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2011	123	Frederic Cren	www.inventivapharma.com

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

Inventiva S.A. Fundamentals Summary

How do Inventiva's earnings and revenue compare to its market cap?
IVA fundamental statistics
Market cap	US$225.76m
Earnings (TTM)	-US$109.28m
Revenue (TTM)	US$20.22m

11.2x

P/S Ratio

-2.1x

P/E Ratio

Is IVA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IVA income statement (TTM)
Revenue	€19.28m
Cost of Revenue	€1.08m
Gross Profit	€18.19m
Other Expenses	€122.38m
Earnings	-€104.19m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Mar 26, 2025

Earnings per share (EPS)	-1.09
Gross Margin	94.38%
Net Profit Margin	-540.52%
Debt/Equity Ratio	-85.6%

How did IVA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/17 21:09
End of Day Share Price	2025/02/14 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Inventiva S.A. is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jean-Jacques Le Fur	Bryan Garnier & Co
Edward Nash	Canaccord Genuity
Stephanie Lefebvre	Gilbert Dupont

IVA Stock Overview

Rewards

Risk Analysis

Inventiva S.A. Competitors

NasdaqCM:VSTM

US$274.2m

NasdaqGM:TLSI

US$172.3m

NasdaqCM:RCEL

US$278.6m

NasdaqGS:VYGR

US$231.1m

Price History & Performance

Recent News & Updates

Inventiva S.A. to Report First Half, 2025 Results on Sep 25, 2025

Inventiva to Present Data from the Final Analysis of the Phase 2 Study Evaluating the Combination of Lanifibranor with Empagliflozin in Patients with Mash and T2d At the Aasld the Liver Meeting® Late-Breaker Session

Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Recent updates

Inventiva S.A. to Report First Half, 2025 Results on Sep 25, 2025

Inventiva to Present Data from the Final Analysis of the Phase 2 Study Evaluating the Combination of Lanifibranor with Empagliflozin in Patients with Mash and T2d At the Aasld the Liver Meeting® Late-Breaker Session

Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Inventiva S.A. to Report Fiscal Year 2022 Results on Mar 29, 2023

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Inventiva Provides Update on Development of cedirogant by AbbVie

Inventiva, Sino Biopharm sign licensing pact to develop, commercialize NASH treatment

Inventiva S.A. to Report First Half, 2022 Results on Sep 21, 2022

Inventiva Announces the Screening of the First Patient in LEGEND , Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D

Inventiva Announces Three Scientific Presentations At the EASL International Liver Congress™ 2022

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva S.A. Announces IND Application for the Phase Ii Combination Trial with Lanifibranor and Empagliflozin in Patients with Nash

Inventiva S.A. to Report Fiscal Year 2021 Results on Mar 07, 2022

Inventiva receives a €4 Million Milestone Payment from AbbVie for Cedirogant Phase IIb Initiation

Inventiva Announces Positive Results of Clinical Thorough QT Study Conducted with Lanifibranor

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $30.00001 million.

Inventiva Announces the Initiation of Its Pivotal Phase III Clinical trial Evaluating Lanifibranor in NASH

Inventiva Announces Collaboration on Non-Invasive Biomarkers to Identify Patients Responding to Lanifibranor with Regards to Nash Resolution and Fibrosis Improvement

Inventiva S.A. to Report First Half, 2021 Results on Sep 20, 2021

Inventiva Announces Design of Phase III Clinical Trial with Lanifibranor in NASH

Inventiva lays out trial design for late-stage lanifibranor study in NASH

Inventiva Announces the Publication in the Journal of Hepatology of New Pre-Clinical Data Showing the Beneficial Effects of Lanifibranor on Cirrhosis

Inventiva S.A. Receives Positive Fda Feedback to Advance Its Lead Drug Candidate Lanifibranor into Pivotal Phase Iii in Nash

Inventiva Announces Appointment of Michael Cooreman as Chief Medical Officer

Inventiva Receives Fda Fast Track Designation in Mps Vi for Its Clinical-Stage Asset Odiparci

Inventiva Receives FDA Breakthrough Therapy Designation for Lead Drug Candidate Lanifibranor in NASH

Inventiva S.A. to Present the Results of Its Native Phase IIb Clinical Trial with Lanifibranor in Nash During Plenary Session at the Liver Meeting Digital Experience™ 2020

Shareholder Returns

Price Volatility

About the Company

Inventiva S.A. Fundamentals Summary

11.2x

-2.1x

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources